louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06894342: Ultrasonographic Evaluation of the Effect of Occlusal Splint Treatment on Masseter Muscle Thickness in Children With Sleep Bruxism:A Clinical Pilot Study
Official title: Ultrasonographic Evaluation of the Effect of Occlusal Splint Treatment on Masseter Muscle Thickness in Children With Sleep Bruxism:A Clinical Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bruxism, Sleep
Keywords: bruxism
child
USG
masseter muscle
occlusal splint
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
First posted: 2025-03-25
Enrollment: 11
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients between the ages of 7 and 12, with mixed dentition, class I occlusion and diagnosed with probable bruxism

Brief summary: The aim of this study was to evaluate the effectiveness of occlusal splint in pediatric bruxist patients by ultrasonic measurements of masseter muscle thickness and pain perception.

Detailed description: The aim of this study was to evaluate the effectiveness of occlusal splint by ultrasonographic measurements of masseter muscle thickness and pain perception in a group of pediatric bruxist patients. The study included patients aged 7 to 12 years, all in the mixed dentition period, with class I occlusion and diagnosed with probable bruxism. A 2 mm thick soft occlusal splint was prepared for each patient. Ultrasonic measurements were used to assess the thickness of the masseter muscle (MMT) at baseline, one, two and three months.Visual Analog Scale (VAS) was also used to record subjective pain measurements. Repeated-measures ANOVA and Friedman test were used in the statistical analysis

Eligibility criteria: Inclusion Criteria:

* Symptoms of tooth clenching or grinding when sleeping at night or during the day, including headaches in the morning, as reported by parents during anamnesis.
* Attrition-type tooth wear, as well as discomfort, fatigue, and/or pain in the jaw muscles when palpated during a clinical examination. The clinical diagnosis of attrition was based on the following findings:

  * Shiny and flat facets.
  * The enamel and dentin wear at the same pace.
  * Wear patterns on opposing teeth's occlusal surfaces.
  * Possible breakage of cusps or restorations.
  * Impressions on the cheeks, tongue, or lips.

Exclusion Criteria:

* Children with any chronic/systemic/psychological disease, presence of TMD symptoms, lack of posterior teeth that may cause unilateral chewing, use of any medication that may affect muscle activity, dental malocclusions (any skeletal jaw problems in anteroposterior and vertical dimensions) and ongoing orthodontic treatment

Primary outcomes:
measure: muscle thickness measurement
timeFrame: from the beginning to the third month
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Yıldırım Beyazıt University
state: Etlik
Study officials:
References:
Clinical trial NCT05392842: Corchorus Olitorius Buccal Films for the Treatment of Recurrent Minor Aphthous Ulcerations
Official title: The Potential of Corchorus Olitorius Seeds Buccal Films for Treatment of Recurrent Minor Aphthous Ulcerations in Human Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Aphthous Ulcer Recurrent
Lead sponsor: Deraya University
Sponsor class: OTHER
First posted: 2022-05-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A methanol extract of Corchorus olitorius edible plant was perpared for extration of glycosideal compounds. the extract was tested for its efficacy as antiinflammatory and analgesic activity invitro and approved by the biomarkers. a fast dissolvinf mucoadhesive film was prepared by a certain amounts of highly safe polymers for a pilote study on human for treament of Aphthous Ulcerations. two groups of study, placebo and intrvention will be recurited and followed for pain, erthymia and size of ulcers for 6 days.


Eligibility criteria: Inclusion Criteria:

1. Males and females aged 18-65 years old
2. Willingness to participate and sign the informed consent forms
3. Presenting with 1 to 5 aphthous ulcers (less than 72 hours' duration) with a size no greater than 5 mm in diameter
4. An expectation that their ulcers normally take 5 or more days to resolve without treatment

Exclusion Criteria:

* A known history of serious drug hypersensitivities 2. Pregnancy and lactation (Urine hCG-positive) 3. Concurrent clinical conditions that could pose a health risk to the subjects, including serious liver, kidney, and heart dysfunctions 4. A history of an immunologic problem

Primary outcomes:
measure: treatment of ulcer
timeFrame: 6 days
Secondary outcomes:
measure: Pain scoring
timeFrame: 6 days
measure: Erthymia
timeFrame: 6 days
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Minya university, faculty of medicin
state: المنيا
Study officials:
References:
Clinical trial NCT00234442: Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
Official title: A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Brain Neoplasms
Non Small Cell Lung Cancer
Keywords: Non symptomatic brain metastases
Iressa
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-10-07
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC


Eligibility criteria: Inclusion Criteria:

* Radiologically confirmed brain metastases from Non Small Cell Lung Cancer
* No symptoms due to brain metastases
* No previous radiotherapy treatment for the Brain metastases

Exclusion Criteria:

* No prior chemotherapy
* No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
* Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)

Primary outcomes:
measure: Disease control rate (complete response, partial response and stable disease)
Secondary outcomes:
measure: Duration of response
measure: Time to progression
measure: Overall Survival
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Research Site
city: Orbassano
country: Italy
facility: Research Site
city: Parma
country: Italy
facility: Research Site
city: Rozzano
country: Italy
facility: Research Site
Study officials:
affiliation: Bologna, Italy
name: Lucio Crino, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00998842: Comparison of a Novel 12-Lead Wireless Electrocardiogram (ECG) and a Standard Wired ECG
Official title: Comparison of a Novel 12-Lead Wireless ECG and a Standard Wired ECG
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: ECG
EKG
healthy subjects
electrocardiography, ambulatory
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
Collaborators: name: Oklahoma State University Center for Health Sciences
First posted: 2009-10-21
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy individuals Age 18-64

Brief summary: To determine if there is a difference between wireless ECG and wired ECG findings.

Detailed description: The aim of the study is to compare ECG recordings from the Signalife Fidelity 100 Wireless 12-lead ECG Monitor System to that of the GE 5000 Wired 12-lead ECG Monitor System during rest and while walking. We hypothesize that ECG recordings from the wireless system will be equivalent to recordings from the standard wired system.

Eligibility criteria: Inclusion Criteria:

* Healthy individuals, AND
* Age 18-64

Exclusion Criteria:

* Pregnant women,
* Prisoners,
* Have known cardiovascular disease, OR
* Do not pass the PAR-Q and/or show baseline ECG abnormalities.

Primary outcomes:
measure: ECG recordings from the wireless system will be equivalent to recordings from the standard wired system.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Tulsa
country: United States
facility: Family Medicine Clinic
state: Oklahoma
Study officials:
References:
Clinical trial NCT04360642: Singing for Wellness: Is Singing a Useful Way of Supporting People in South Devon to Self-manage Aspects of Their COPD
Official title: Singing for Wellness: Is Singing a Useful Way of Supporting People in South Devon to Self-manage Aspects of Their COPD: Does a Bespoke Respiratory Choir Provide a Non-medical Intervention for Those With COPD in Our Local Community
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD
Lead sponsor: Torbay and South Devon NHS Foundation Trust
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to explore whether singing is a useful way of supporting people in South Devon to self manage aspects of their COPD and associated social isolation. It will also investigate whether a model of bespoke respiratory community choirs provides a useful service for our local community. The study will look at the impact of singing on breathing, wellbeing, frailty and engagement.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with COPD

  * Evidence of airflow obstruction as measured by spirometry
  * Being independently mobile and able to get to location
  * Being able to give permission to participate
  * Over 18 years old
  * Awaiting pulmonary rehabilitation or have completed pulmonary rehabilitation

Exclusion Criteria:

* Lacking capacity to give permission to participate e.g. severe dementia

  * Other health issues which preclude participation e.g. psychosis, unstable physical health
  * Under 18 years of age
  * Not diagnosed with COPD

Primary outcomes:
measure: Lung function
timeFrame: 12 weeks
measure: Lung function
timeFrame: 12 weeks
measure: Lung function
timeFrame: 12 weeks
Secondary outcomes:
measure: Mental Wellbeing
timeFrame: 12 weeks
measure: Frailty
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Torquay
country: United Kingdom
facility: Torbay Hospital
state: Devon
Study officials:
affiliation: Torbay and South Devon NHS Foundation Trust
name: Fiona Roberts
role: STUDY_DIRECTOR
References:
Clinical trial NCT00406042: The Role of Steroids Following Selective Laser Trabeculoplasty
Official title: The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: glaucoma
trabeculoplasty
steroids
Lead sponsor: West Virginia University
Sponsor class: OTHER
First posted: 2006-12-04
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate whether or not using topical steroids after selective laser trabeculoplasty affects intraocular pressure outcomes.

Detailed description: Subjects undergoing bilateral SLT will be randomly assigned to use prednisolone acetate 1% in one eye four times daily with no treatment in the fellow eye, for one week following SLT. Examinations will occur at baseline, and one week, one month and three months after SLT. IOP and anterior chamber inflammation will be noted at each visit.

Eligibility criteria: Inclusion Criteria:

* glaucoma or ocular hypertension
* need for bilateral SLT

Exclusion Criteria:

* eye disease precluding accurate IOP measurement
* contraindication to topical prednisolone acetate

Primary outcomes:
measure: Intraocular pressure reduction
Secondary outcomes:
measure: Anterior chamber inflammation
Other outcomes:
Locations:
city: Morgantown
country: United States
facility: West Virginia University Eye Institute
state: West Virginia
Study officials:
affiliation: West Virginia University Eye Institute
name: Tony Realini, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Realini T, Charlton J, Hettlinger M. The impact of anti-inflammatory therapy on intraocular pressure reduction following selective laser trabeculoplasty. Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):100-3. doi: 10.3928/15428877-20091230-18.
Clinical trial NCT01230242: Postplacental Mirena IUD Insertion and Estimating Expulsion Rates.
Official title: Experimental Study Examining Mirena IUD Insertion and Estimating Rates of Expulsion Immediately After Placental Delivery.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Estimating Rates of Expulsion
Keywords: Mirena
postplacental intrauterine device
postpartum insertion
Lead sponsor: MaineHealth
Sponsor class: OTHER
Collaborators: name: MaineHealth
First posted: 2010-10-29
Enrollment: 4
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Mirena IUD placement
Primary purpose: TREATMENT

Brief summary: This study aims to demonstrate that the expulsion rate is increased but acceptable when inserting Mirena IUDs immediately postpartum, termed 'postplacental IUD insertion'. The investigators will compare the postplacental insertion expulsion rate estimate with rates reported in the literature for 6 week postpartum insertion, which is currently the American standard for IUD insertion postpartum. Secondary outcomes will also be examined; endometritis, uterine perforation, continuation and pregnancy among others.

Detailed description: The average expulsion rate for 6 week postpartum IUD insertion is approximately 10-12% with a range between 3-20% at 1 year. An acceptable expulsion rate for postplacental insertion (PPI) has not been defined and varies between studies. There are limited data on the expulsion rates of levonorgestrel intrauterine systems. Expulsion rates range widely from 1-3% to as high as 30-40% depending on the IUD and the study. Studies report an average rate of expulsion in ranges approximating 10-12%, similar to 6 week insertion rates.

There are many limitations to published studies including the use of older model IUDs no longer in use, multiple insertion techniques that have been deemed ineffective in reducing expulsion rates as well as varying follow up times making comparison of expulsion rates difficult.

Eligibility criteria: Inclusion Criteria:

* age 18 or greater
* obstetric patient in greater Portland, ME area

Exclusion Criteria:

* Evidence of chorioamnionitis (persistent fetal tachycardia, intra-partum fever \>38.0)
* prolonged rupture of membranes (greater than 24 hours)
* intrauterine fetal demise
* use of general anesthesia at time of delivery
* postpartum hemorrhage (\>500ml vaginal, \>1000ml cesarean)
* magnesium administration in labor due to HELLP syndrome or preeclampsia
* preterm delivery.

Primary outcomes:
measure: Number of Participants Who Expelled IUDs by12 Weeks Postpartum
timeFrame: up to 12 weeks postpartum
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: MaineHealth
name: Jennifer J Mueller, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00703742: A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
Official title: A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Depression Secondary to Other Disease
Lead sponsor: Kunming Medical University
Sponsor class: OTHER
Collaborators: name: Chinese Academy of Sciences
First posted: 2008-06-23
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is:

1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
4. to find possible predispose to MDD
5. to explore the DNA methylation status in depression;

Detailed description: 1. to explore the pathology of depression
2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Eligibility criteria: Inclusion Criteria:

* DSM-IV Major Depression or Dysthymia
* Age 18-65
* Physically healthy
* Drug-free

Exclusion Criteria:

* Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
* History of Psychosis or Epilepsy
* Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
* Bipolar I
* Need for wash-out from effective treatment in order to participate
* Pregnant
* High suicide risk
* Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants

Primary outcomes:
measure: change of fMRI after medication
timeFrame: baseline, 4 weeks, 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kunming
country: China
facility: The First Affiliated Hospital of Kunming Medical College
state: Yunnan
Study officials:
affiliation: Kunming Medical University
name: Xu Xiufeng
role: STUDY_DIRECTOR
References:
citation: Cheng Y, Xu J, Yu H, Nie B, Li N, Luo C, Li H, Liu F, Bai Y, Shan B, Xu L, Xu X. Delineation of early and later adult onset depression by diffusion tensor imaging. PLoS One. 2014 Nov 13;9(11):e112307. doi: 10.1371/journal.pone.0112307. eCollection 2014.
citation: Xu J, Cheng Y, Chai P, Lu Z, Li H, Luo C, Li X, Li L, Zhou Q, Chen B, Cao J, Xu X, Shan B, Xu L, Wen J. White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging. J Rheumatol. 2010 May;37(5):974-86. doi: 10.3899/jrheum.090967. Epub 2010 Mar 15.
Clinical trial NCT03099642: Ultrasound-Assisted Lumbar Puncture in Children
Official title: Emergency Physician Performed Ultrasound-Assisted Lumbar Puncture in a Pediatric Population: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fever
Keywords: lumbar puncture
Point of care ultrasound
children
Lead sponsor: St. Justine's Hospital
Sponsor class: OTHER
First posted: 2017-04-04
Enrollment: 166
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to determine if emergency physician performed ultrasound-assisted lumbar puncture improves first-time success rates in a pediatric population. This will be done by comparison with current landmark-based approach to the procedure.


Eligibility criteria: Inclusion Criteria:

* Patient less than 19 years of age
* Requiring a lumbar puncture as part of their work-up, as determined by the treating pediatric emergency physician.

Exclusion Criteria:

* • Patients with known spine or spinal cord abnormalities

  * Patients with ventricular shunts
  * Patients deemed too unstable to have procedure performed
  * Patients at risk for significant bleeding (coagulopathy, thrombocytopenia, etc)
  * Parents unable to give consent or patients unable to assent for an acute reason

Primary outcomes:
measure: First-tie success
timeFrame: 15 minutes
Secondary outcomes:
measure: Total lumbar puncture success rate
timeFrame: 15 minutes
measure: Change in performer
timeFrame: 15 minutes
measure: Time of procedure
timeFrame: 30 minutes
measure: Complication
timeFrame: 30 minutes
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Sainte-Justine Hospital
state: Quebec
Study officials:
affiliation: Sainte-Justine Hospital
name: Jocelyn Gravel, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00710242: Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Assess the Safety and Efficacy or Pre-Treatment With DF01 During Late Pregnancy in Reducing Prolonged Labor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pregnancy
Labor
Keywords: prolonged labor
Lead sponsor: Dilafor AB
Sponsor class: INDUSTRY
First posted: 2008-07-04
Enrollment: 263
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is a Proof-of-concept study to evaluate if DF01 can prevent protracted labor. Time to delivery will be measured from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes.


Eligibility criteria: Inclusion Criteria:

* healthy nulliparous females
* normal singleton pregnancy
* intact membranes

Exclusion Criteria:

* breech or other abnormal presentation
* intercurrent illness
* pregnancy complications
* vaginal bleeding in third trimester
* etc

Primary outcomes:
measure: Time from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes until partus in women with vaginal delivery
timeFrame: See above
Secondary outcomes:
measure: Complications of labor
timeFrame: At delivery
Other outcomes:
Locations:
city: Boras
country: Sweden
facility: Kvinnokliniken Alvsborgs sjukhus Boras
city: Gavle
country: Sweden
facility: Gavle sjukhus
city: Goteborg
country: Sweden
facility: Sahlgrenska/Ostra sjukhuset
city: Huddinge
country: Sweden
facility: Karolinska Universistetssjuhuset
city: Jonkoping
country: Sweden
facility: Lanssjukhuset Ryhov
city: Kalmar
country: Sweden
facility: Lanssjukhuset
city: Linkoping
country: Sweden
facility: Universitetssjukhuset
city: Lund
country: Sweden
facility: Universitetssjukhuset
city: Norrköping
country: Sweden
facility: Vrinnevisjukhuset
city: Nyköping
country: Sweden
facility: Nyköpings lasarett
city: Skövde
country: Sweden
facility: Kärnsjukhuset
city: Stockholm
country: Sweden
facility: Danderyds sjukhus
city: Stockholm
country: Sweden
facility: Sodersjukhuset
city: Trollhättan
country: Sweden
facility: Norra Älvsborgs länssjukhus
city: Uppsala
country: Sweden
facility: Akademiska sjukhuset
city: Vasteras
country: Sweden
facility: Centrallasarettet
city: Växjö
country: Sweden
facility: Centrallasarettet
city: Örebro
country: Sweden
facility: Universitetssjukhuset
Study officials:
affiliation: Kvinnokliniken Sodra Alvsborgs sjukhus Boras
name: Lena Granstrom, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dilafor AB
name: Gunvor Ekman-Ordeberg, MD, PhD
role: STUDY_CHAIR
References: